Kadance, Inc.

Kadance, Inc. , based in the US, specializes in genetic testing and health management, delivering personalized insights to enhance health outcomes through comprehensive analysis and tailored strategies. Kadance, Inc. was founded in 2021 by CEO Darren Rowe and operates out of Huntsville, US, focusing on precision health solutions.

The company has engaged in one significant deal thus far, with the most recent investment occurring on March 19, 2026, raised by Oncology Ventures. . Kadance specializes in Precision Health Management, providing personalized insights through genetic testing and health guidance. Its core offerings include comprehensive analysis of inherited cancer risks, medication effectiveness, and tailored health management strategies.

The company targets both individual consumers and healthcare providers in the United States, addressing the demand for personalized healthcare solutions. Kadance generates revenue through direct-to-consumer sales and partnerships with healthcare providers. Clients engage with its services via subscription plans, which include genetic testing and health consultations. The pricing structure is designed to ensure accessibility while reflecting the value of personalized health insights.

Flagship services such as cancer risk assessments are central to the revenue model, supporting a steady revenue stream for the company. In March 2026, Kadance, Inc. raised an undisclosed amount of venture funding from new investor Oncology Ventures. This funding will be allocated to support the integration of genomics-based precision diagnostics, oncology services, and care navigation into insurance products.

The company is also working on upcoming products designed to enhance its health management offerings, focusing on expanding its reach in the precision health market.